Marker Therapeutics (MRKR) Accounts Payables (2010 - 2026)

Marker Therapeutics (MRKR) has 17 years of Accounts Payables data on file, last reported at $1.9 million in Q1 2026.

• Accounts Payables for Q1 2026 came in at $1.9 million, down 8.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.9 million (down 8.44% YoY), and the FY2025 annual result was $1.3 million, down 25.92% from the prior year.
• Accounts Payables climbed to $1.9 million in Q1 2026 per MRKR's latest filing, from $1.3 million in the prior quarter.
• Over five years, Accounts Payables peaked at $7.3 million in Q1 2022 and troughed at $1.3 million in Q4 2025.
• A 5-year average of $2.9 million and a median of $2.3 million in 2025 frame the typical range for Accounts Payables.
• On a YoY basis, Accounts Payables climbed as much as 289.25% in 2022 and fell as far as 77.36% in 2022.
• A 5-year view of Accounts Payables shows it stood at $2.5 million in 2022, then slumped by 30.78% to $1.7 million in 2023, then rose by 0.5% to $1.8 million in 2024, then decreased by 25.92% to $1.3 million in 2025, then jumped by 47.28% to $1.9 million in 2026.
• Business Quant data shows MRKR's Accounts Payables at $1.9 million in Q1 2026, $1.3 million in Q4 2025, and $1.7 million in Q3 2025.